Quintiles Library

promo_digital_graphs
Featured Video

Predictive and Advanced Analytics
Sr. VP of Data Sciences & Strategy Margaret Keegan discusses how new Predictive and Advanced Analytics provides identification of potential patient safety issues and actionable insight into clinical trial site performance. ...
Show Filters
Press Release
RESEARCH TRIANGLE PARK, N.C. and MADISON, N.J. – July 2, 2015 – Quintiles and Quest Diagnostics today announced the launch of Q2 Solutions, their new combined clinical trials laboratory services organization. Q2 Solutions brings together the clinical trials laboratory operations of the two parent organizations to provide biopharmaceutical customers with the diverse capabilities and end-to-end services required in the rapidly evolving biopharmaceutical industry. Today’s launch of Q2 Solutions is the result of the close of the previously announced global clinical trials laboratory services joint-venture transaction. Q2 Solutions is strongly positioned as the second-largest central laboratory services company in the world and provides services to customers across all segments of the...
Read More
Press Release
RESEARCH TRIANGLE PARK, N.C. – July 1, 2015 – Quintiles Transnational Holdings Inc. (NYSE: Q) will release its second-quarter 2015 financial results Wednesday, July 29, 2015 prior to its quarterly earnings call at 8:00 a.m. EDT. The conference call will be accessible, live via webcast, on the Investor Relations section of the Quintiles website at www.quintiles.com/investors. To participate via telephone, please dial +1 (855) 710-5091 in the United States or +1 (706) 902-0591 outside the United States, approximately 15 minutes before the scheduled start of the call. An archived edition of the conference call will be available online at www.quintiles.com/investors after 1:00 p.m. EDT on Wednesday, July 29th. About Quintiles Quintiles (NYSE: Q) helps biopharma and other healthcare...
Read More
White Paper
This insight brief explores the benefits of Model-based Drug Development (MBDD) for emerging biopharma companies. MBDD is the process of leveraging modeling and simulation throughout the project life cycle to predict trial results and inform planning and design decisions. MBDD is a proven and often effective method for reducing the costly delays and changes that plague typical development efforts by enabling project teams to select the right dose, estimate patient recruitment, and optimize protocol, study and program...
Explore More
Fact Sheet
Historically, lifecycle management (LCM) has been focused primarily on market expansion and product life extension. However in today’s rapidly changing healthcare environment, this is no longer enough. You must also focus on product protection and differentiation as strategies for delivering real value to all stakeholders in the healthcare system. At Quintiles, we believe in order for your product to succeed in the changing health landscape, you must implement an integrated lifecycle management strategy that meets payer...
Read More
Fact Sheet
Understanding the needs of local payers is more important than ever for biopharma. It can be challenging to uncover the key requirements of a local market, and even more difficult to prove how a drug can help fulfill the unmet needs of the local population. With payers becoming more sophisticated in their evidentiary needs, Clinical Commissioning Groups (CCGs) now require data that is tailored to their local healthcare economy. The data generated needs to go beyond regulatory approval; it needs to prove cost effectiveness, provide checkpoints between payer and biopharma, and ensure the removal of any uncertainties that may result in barriers to market access. Quintiles has a network of strong local market access teams to help support you in reaching local decision makers and...
Read More
Fact Sheet
Non-adherence to medicine is a major concern for the UK health economy. The National Institute for Health and Care Excellence (NICE) estimates that £4 billion of medicine is currently not used correctly, and as a result, biopharma must strive to understand the varying types and causes of non-adherence. The local care pathway should be under focus if biopharma is to tackle nonadherence. By using real patient and treatment data to analyze core pathway frailties that contribute to non-adherence. solutions can be developed to help improve that core pathway, and more critically, explore what motivates individual patients to adhere. Where a patient is on the treatment pathway is also vital, as recently diagnosed patients have different needs to those who have lived for several years with a...
Read More
Fact Sheet
At Quintiles, our goal is to deliver rapid and predictable study timelines with enhanced quality, greater efficiencies and improved outcomes in the execution of your global vaccine programs. Read our fact sheet to learn...
Read More
Expert
A patient registry is defined as "an organized system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure. A registry also serves one of more predetermined scientific, clinical, or policy purposes." Patient registries may be used for a variety of purposes, including one or more of the following: effectiveness research for drugs or devices, natural history of disease, post-marketing commitments or safety monitoring, quality improvement programs, certification programs (e.g., for physicians to retain membership in a professional medical organization), and surveillance programs (e.g., to track vaccination...
Read More
Fact Sheet
Pediatric studies require specialized expertise to ensure study design and protocol-required procedures are appropriate for children and include support for the family during the trial. Through our Pediatric Center of Excellence, Quintiles brings together the therapeutic, regulatory and operational expertise to help you design and execute a feasible pediatric...
Read More
Fact Sheet
The Asia Pacific Emerging Biopharma Solution provides dedicated and numble operational support combined with Quintiles' unmathced depth of expertise and breadth of perspective across the...
Read More
Fact Sheet
Quintiles brings together scientific and therapeutic expertise, experienced oncology teams, and integrated global trial operations to help improve your probability of success. We help extend the capabilities of your oncology teams across the product lifecycle – and across the globe – to help you gather the evidence needed to gain regulatory approval and accelerate market adoption. As a testament to our commitment, we helped develop or commercialize 100% of the Top 30 best-selling oncology products of...
Read more
Press Release
RESEARCH TRIANGLE PARK, N.C. – June 16, 2015 – Quintiles, the world’s largest biopharmaceutical services company, is extending its award-winning Quintiles Infosario® technology platform with mobile access to critical clinical trial information. Using the mobile app, key stakeholders in the drug development process can conveniently access site start-up, recruitment and compliance information as well as status updates on data queries and project milestones. “With so much at stake in the successful delivery of development programs, faster decision making is fundamental,” said Margaret Keegan, senior vice president of Data Sciences & Strategy at Quintiles. “Infosario One provides instant and intuitive access to insights at your fingertips, wherever and whenever you need them.” The Infosario...
Read More
Fact Sheet
Developing cancer treatments requires the right strategic approach to manage risks and make critical go/no-go decisions. Partner with Quintiles for the global scientific, clinical and technological resources needed for successful oncology drug...
Read More
Press Release
RESEARCH TRIANGLE PARK, N.C. – June 15, 2015 – Quintiles, the world’s largest biopharmaceutical services company, today announced the addition of advanced statistical monitoring and predictive analytics capabilities to its risk-based monitoring (RBM) solution. Predictive and Advanced Analytics combine Quintiles’ experience as the RBM leader with its deep therapeutic and strong statistical sciences heritage to enable study teams to identify the right signals and predict clinical trial site performance and potential patient safety issues. Predictive and Advanced Analytics are the first such model-based capabilities fully integrated into an RBM solution on the market today. Underpinned by the award-winning Quintiles Infosario® technology platform and Quintiles’ deep data resources, these new...
Read More
White Paper
This white paper seeks to give an overview on medication adherence, examining the financial costs of non-adherence and analyzing the importance of real-world adherence data for maximizing the commercial value of a product. In a healthcare economy that is under pressure to provide cost savings, biopharma must demonstrate a long-term commitment to supporting health systems through effective adherence support programs. A patient-centric approach that includes education and emotional support is vital to improve adherence, and the expertise and knowledge provided by nurse educators (NEs) is fundamental for biopharma. Advances in technology and the digitization of patient services can also support the delivery of a patient-centric approach that empowers patients to make informed decisions about...
Explore More
Video
To make better, faster decisions, you need instant insight into your studies. With Infosario One, you have easy and better access to your clinical trial information – whenever and wherever you need it. ...
Video
Dr. Oren Cohen explains the enormous public health advances that have been made through vaccine research. ...
Video
Quintiles’ Chief Information Officer Alejandro Martinez and Sr. VP of Data Sciences & Strategy Margaret Keegan discuss the new Infosario® One mobile app that provides customers with instant and intuitive access to clinical trial data at their fingertips — wherever and whenever they need it. Get started with the Infosario One app, learn more. ...
Media Coverage
The EMA policy on publication of clinical data for medicinal products for human use that came into effect on 1 January 2015 requires the centralized publication of clinical trial results, but it does not resolve the more thorny issue of access to individual patient data (IPD) relative to clinical trial results disclosure. This article, found on pp. 26-29, discusses transparency trends and the importance of continuing to protect the privacy rights of...
Read More
Fact Sheet
The new paradigm of precision medicine is changing the oncology drug development...
Read More